A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients.

[1]  S. Passik,et al.  A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. , 2002, Journal of pain and symptom management.

[2]  F. Bymaster,et al.  Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. , 2001, European journal of pharmacology.

[3]  S. Passik,et al.  The changeable nature of patients' fears regarding chemotherapy: implications for palliative care. , 2001, Journal of pain and symptom management.

[4]  R. Aparasu,et al.  Opioid-induced emesis among hospitalized nonsurgical patients: effect on pain and quality of life. , 1999, Journal of pain and symptom management.

[5]  R. Portenoy,et al.  Principles and Practice of Supportive Oncology , 1998 .

[6]  Philip Seeman,et al.  Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine , 1996, Neuropsychopharmacology.

[7]  M. Millan,et al.  Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. , 1995, The Journal of pharmacology and experimental therapeutics.

[8]  D. Sibley,et al.  Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. , 1994, The Journal of pharmacology and experimental therapeutics.

[9]  Sandra E. Ward,et al.  Patient-related barriers to management of cancer pain , 1993, Pain.

[10]  H. Meltzer,et al.  Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. , 1989, The Journal of pharmacology and experimental therapeutics.

[11]  W. Pirl,et al.  Remission of chemotherapy‐induced emesis with concurrent olanzapine treatment: a case report , 2000, Psycho-oncology.

[12]  R. Sweet,et al.  Reliability and applicability of movement disorder rating scales in the elderly. , 1993, The Journal of neuropsychiatry and clinical neurosciences.